This study looks at a new medicine called **Saruparib**. It’s being tested with standard treatments for prostate cancer, a disease that affects a man's prostate gland. The study involves men with a genetic change called a BRCA mutation, which is linked to higher cancer risk. The goal is to see if Saruparib helps patients live longer without cancer spreading, compared to those taking a placebo (a pill with no medicine).

Participants are split into two groups. Both groups receive Saruparib or a placebo, along with treatments called Radiation Therapy (RT) and Androgen Deprivation Therapy (ADT). Some also take another medicine called Abiraterone. The study involves about 700 men and will track their health and survival. Doctors will check safety and effectiveness regularly.

• Duration: Participants are tracked until the study ends, with regular check-ups.
• Eligibility: Males with specific prostate cancer types and BRCA mutation.
• Exclusions: Certain health conditions and previous treatments can disqualify participation.